Lyell Immunopharma, Inc. (LYEL) Investor Relations Documents

Lyell Immunopharma, Inc. (LYEL) investor relations documents from the company's IR site: 1 presentation, 18 press releases; latest deck 2026-08-06. Read in-app with summaries. First-party data.

Company Presentation: Lyell Immunopharma is developing next-generation CAR T-cell therapies, with lead candidate Ronde-cel targeting a BLA submission in 2H 2027 for R/R LBCL.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06PresentationCompany Presentation
2026-08-06Press releaseLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
2026-07-21Regulatory report9999999995-26-002375.pdf
2026-06-25Press releaseLyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-12Press releaseLyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in
2026-06-08Press releaseLyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer an
2026-06-04Press releaseLyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the Euro
2026-06-01Press releaseLyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
2026-05-12Press releaseLyell Immunopharma Announces Participation in May Investor Conferences
2026-05-06Press releaseLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
2026-04-07Press releaseLyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
2026-03-12Press releaseLyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
2026-02-23Press releaseLyell Immunopharma Announces Participation in March Investor Conferences
2026-02-12Press releaseLyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical
2025-12-07Press releaseLyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Res
2025-11-10Press releaseLyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Develo
2025-11-03Press releaseLyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive La
2025-09-03Press releaseLyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive La
2025-09-02Press releaseLyell Immunopharma Announces Participation in September Investor Conferences
Press releaseOrca Bio and Lyell Immunopharma Announce Research Partnership

LYEL overview · LYEL earnings · LYEL financials · LYEL KPIs · LYEL ownership · LYEL peers · LYEL filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.